Description: Tremendous progress has been made in understanding the molecular mechanisms underlying the neuropathology of Parkinson's disease (PD). Aside from genetic mutations that give rise to familial form of this disorder, current clinical diagnosis is mainly based on physical examination, and measures to predict and stop disease development remain elusive. This webinar provides an overview of discovery and validation of biomarkers such as α-Synuclein that could serve as an indicator of pathogenic process and/or evaluate therapeutic efficacy of drug treatments for PD.